:
The cost-effective production of high-quality and biologically active recombinant
molecules especially proteins is extremely desirable. Seed-based recombinant protein production
platforms are considered as superior choice owing to lack of human/animal pathogenic organisms,
lack of cold chain requirements for transportation and long-term storage, easy scalability and
development of edible biopharmaceuticals in plants with objective to be used in purified or partially
processed form is desirable. This review article summarizes the exceptional features of seed-based
biopharming and highlights the needs of exploiting it for commercial purposes. Plant seeds offer a
perfect production platform for high-value molecules of industrial as well as therapeutic nature
owing to lower water contents, high protein storage capacity, weak protease activity and long-term
storage ability at ambient temperature. Exploiting extraordinarily high protein accumulation
potential, vaccine antigens, antibodies and other therapeutic proteins can be stored without effecting
their stability and functionality up to years in seeds. Moreover, ability of direct oral consumption
and post-harvest stabilizing effect of seeds offer unique feature of oral delivery of pharmaceutical
proteins and vaccine antigens for immunization and disease treatment through mucosal as well as
oral route.
Modelling the relative benefits of using the measles vaccine outside cold chain for outbreak response
